1,519 reports of this reaction
2.5% of all OXCARBAZEPINE reports
#5 most reported adverse reaction
DIZZINESS is the #5 most commonly reported adverse reaction for OXCARBAZEPINE, manufactured by Novartis Pharmaceuticals Corporation. There are 1,519 FDA adverse event reports linking OXCARBAZEPINE to DIZZINESS. This represents approximately 2.5% of all 60,018 adverse event reports for this drug.
OXCARBAZEPINE has an overall safety score of 85 out of 100. Patients taking OXCARBAZEPINE who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is a less commonly reported adverse event for OXCARBAZEPINE, but still significant enough to appear in the safety profile.
In addition to dizziness, the following adverse reactions have been reported for OXCARBAZEPINE:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 1,519 FDA reports for OXCARBAZEPINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 2.5% of all adverse event reports for OXCARBAZEPINE, making it a notable side effect.
If you experience dizziness while taking OXCARBAZEPINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.